Management of progressive pulmonary fibrosis associated with connective tissue disease

Expert Rev Respir Med. 2022 Jul;16(7):765-774. doi: 10.1080/17476348.2022.2107508. Epub 2022 Aug 5.

Abstract

Introduction: Fibrotic interstitial lung disease (ILD) is a frequent and severe complication of connective tissue disease (CTD).

Areas covered: In this narrative review, we update the most relevant differential characteristics of fibrotic ILD associated with CTD (CTD-ILD) and propose a diagnostic and therapeutic approach based on a review of the articles published between 2002 and 2022 through PubMed.

Expert opinion: The subset of ILD, mainly the radiological/histological pattern and the degree of fibrotic component, usually determines the prognosis and therapeutic strategy for these patients. Some patients with CTD-ILD can develop progressive pulmonary fibrosis (PPF) with severe deterioration of lung function, rapid progression to chronic respiratory failure, and high mortality. PPF has been described in many CTDs, mainly in systemic sclerosis and rheumatoid arthritis, and requires a multidisciplinary diagnostic and therapeutic approach to improve patient outcomes.

Keywords: Interstitial lung disease; connective tissue disease; diagnosis; multidisciplinary consultation; progressive pulmonary fibrosis; treatment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Connective Tissue Diseases*
  • Humans
  • Lung Diseases, Interstitial*
  • Prognosis
  • Pulmonary Fibrosis*
  • Scleroderma, Systemic*